Get startedLog in
    Picture of Humanigen logo

    HGENQ — Humanigen News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Humanigen Says First Patient Dosed In Phase 2 Precision Medicine Study Of Lenzilumab In Patients With Chronic Myelomonocytic Leukemia

    Picture of Humanigen logoHumanigen
    26/10/2021 11:44
    Oct 26 (Reuters) - Humanigen Inc  HGEN.O :
    * FIRST PATIENT DOSED IN PHASE 2 PRECISION MEDICINE STUDY OF
LENZILUMAB IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
(CMML)

Source text for Eikon:  ID:nBw1X9Qy3a 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Humanigen

    See all news